Biennial Progress Report of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), 35393-35394 [2012-14436]
Download as PDF
Federal Register / Vol. 77, No. 114 / Wednesday, June 13, 2012 / Notices
Toyota to retain documents relating to
its compliance with the order. For most
records, the order requires that the
documents be retained for a five-year
period. For the third party assessments
and supporting documents, Franklin
Toyota must retain the documents for a
period of three years after the date that
each assessment is prepared. Part VI
requires dissemination of the order now
and in the future to persons with
responsibilities relating to the subject
matter of the order. Part VII ensures
notification to the FTC of changes in
corporate status. Part VIII mandates that
Franklin Toyota submit a compliance
report to the FTC within 90 days, and
periodically thereafter as requested. Part
IX is a provision ‘‘sunsetting’’ the order
after twenty (20) years, with certain
exceptions.
The purpose of the analysis is to aid
public comment on the proposed order.
It is not intended to constitute an
official interpretation of the proposed
order or to modify its terms in any way.
By direction of the Commission.
Richard C. Donohue,
Acting Secretary.
35393
GENERAL SERVICES
ADMINISTRATION
Dated:
Dan Tangherlini,
Acting Administrator of General Services.
[FMR Bulletin–PBS–2012–03; Docket 2012–
0002; Sequence 11]
U.S. GENERAL SERVICES
ADMINISTRATION
Federal Management Regulation; FMR
Bulletin PBS–2012–03; Redesignations
of Federal Buildings
REDESIGNATIONS OF FEDERAL
BUILDINGS
Public Buildings Service (PBS),
General Services Administration (GSA).
SUBJECT: Redesignations of Federal
Buildings
AGENCY:
ACTION:
Notice of a bulletin.
The attached bulletin
announces the designation and
redesignation of three Federal buildings.
Expiration Date: This bulletin
announcement expires October 31,
2012. The building designation and
redesignations remains in effect until
canceled or superseded by another
bulletin.
SUMMARY:
U.S.
General Services Administration, Public
Buildings Service (PBS), 1800 F Street
NW., Washington, DC 20405, telephone
number: (202) 501–1100.
FOR FURTHER INFORMATION CONTACT:
[FR Doc. 2012–14372 Filed 6–12–12; 8:45 am]
BILLING CODE 6750–01–P
TO: Heads of Federal Agencies
1. What is the purpose of this
bulletin? This bulletin announces the
designation and redesignation of three
Federal buildings.
2. When does this bulletin expire?
This bulletin announcement expires
October 31, 2012. The building
designation and redesignations remain
in effect until canceled or superseded by
another bulletin.
3. Designation. The name of the
designated property (between the
United States Federal Courthouse and
the Ed Jones Building located at 109
South Highland Avenue in Jackson,
Tennessee) is as follows:
M.D. Anderson Plaza
Jackson, TN 38301
4. Redesignation. The former and new
names of the redesignated buildings are
as follows:
Former name
New name
United States Courthouse, 80 Lafayette Street, Jefferson City, MO
65101.
United States Courthouse, 222 West 7th Avenue, Anchorage, AL
99501.
Christopher S. Bond United States Courthouse, 80 Lafayette Street,
Jefferson City, MO 65101.
James M. Fitzgerald United States Courthouse, 222 West 7th Avenue,
Anchorage, AL 99501.
5. Who should we contact for further
information regarding redesignation of
these Federal buildings? U.S. General
Services Administration, Public
Buildings Service (PBS), 1800 F Street,
NW., Washington, DC 20405, telephone
number: (202) 501–1100.
Dated: June 7, 2012
Dan Tangherlini,
Acting Administrator of General
Services.
[FR Doc. 2012–14416 Filed 6–12–12; 8:45 am]
BILLING CODE 6820–23–P
erowe on DSK2VPTVN1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Biennial Progress Report of the
Interagency Coordinating Committee
on the Validation of Alternative
Methods (ICCVAM)
Division of the National
Toxicology Program (DNTP), National
Institute of Environmental Health
AGENCY:
VerDate Mar<15>2010
14:45 Jun 12, 2012
Jkt 226001
Sciences (NIEHS), National Institutes of
Health (NIH).
ACTION: Availability of Report.
The NTP Interagency Center
for the Evaluation of Alternative
Toxicological Methods (NICEATM)
announces the availability of the
Biennial Progress Report 2010–2011:
Interagency Coordinating Committee on
the Validation of Alternative Methods.
The report was prepared in accordance
with requirements of the ICCVAM
Authorization Act of 2000 (42 U.S.C.
285l–3).
The Biennial Progress Report
describes activities and progress by
NICEATM and ICCVAM during the
period from January 2010 through
December 2011. During the past two
years, NICEATM, ICCVAM, and
ICCVAM member agencies contributed
to the national and international
endorsement and adoption of 14 new
and updated alternative safety testing
methods. Since ICCVAM was
SUMMARY:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
established, NICEATM, ICCVAM, and
the ICCVAM member agencies have
contributed to the regulatory acceptance
of over 50 alternative methods that can
be used to protect the health of people,
animals, and the environment while
reducing, refining, and replacing animal
use.
The Biennial Progress Report is
available on the NICEATM–ICCVAM
Web site at https://iccvam.niehs.nih.gov/
about/ICCVAMrpts.htm. Copies can also
be requested from NICEATM (see
‘‘ADDRESSES’’).
Requests for copies of the
report should be sent by mail, fax, or
email to Dr. William S. Stokes, Director,
NICEATM, NIEHS, P.O. Box 12233,
Mail Stop: K2–16, Research Triangle
Park, NC 27709, (telephone) 919–541–
2384, (fax) 919–541–0947, (email)
niceatm@niehs.nih.gov. Courier address:
NICEATM, NIEHS, Room 2034, 530
Davis Drive, Morrisville, NC 27560.
ADDRESSES:
E:\FR\FM\13JNN1.SGM
13JNN1
35394
Federal Register / Vol. 77, No. 114 / Wednesday, June 13, 2012 / Notices
Dr.
William S. Stokes, NICEATM Director
(phone 919–541–2384 or
niceatm@niehs.nih.gov).
FOR FURTHER INFORMATION CONTACT:
SUPPLEMENTARY INFORMATION:
Background
The ICCVAM Authorization Act of
2000 established ICCVAM as a
permanent interagency committee of
NIEHS under NICEATM. The Act
directs ICCVAM to coordinate
interagency technical reviews of
proposed new, revised, and alternative
testing methods, including those that
may reduce, refine (enhance animal
well-being and lessen or avoid pain and
distress), and replace animal use.
ICCVAM prepares test method
recommendations based on their
scientific validity for regulatory safety
testing, and submits these
recommendations through the HHS
Secretary (or designee) to U.S. Federal
Agencies for adoption decisions.
A provision of the ICCVAM
Authorization Act states that ICCVAM
shall prepare ‘‘reports to be made
available to the public on its progress
under this Act,’’ with the first report to
be completed within 12 months of
enactment of the Act, and subsequent
reports to be made biennially thereafter.
The fifth ICCVAM biennial progress
report, which summarizes ICCVAM
activities and accomplishments for the
years 2010 and 2011, is now available.
erowe on DSK2VPTVN1PROD with NOTICES
Summary of Report Highlights
The Biennial Progress Report
describes new initiatives and progress
by NICEATM and ICCVAM during the
period from January 2010 through
December 2011. During the past two
years, NICEATM, ICCVAM, and
ICCVAM member agencies contributed
to the national and international
endorsement and adoption of 14 new
and updated alternative safety testing
methods. Since ICCVAM was
established, NICEATM, ICCVAM, and
the ICCVAM member agencies have
contributed to the regulatory acceptance
of over 50 alternative methods that can
be used to protect and improve the
health of people, animals, and the
environment while reducing, refining,
and replacing animal use.
Selected highlights of NICEATM and
ICCVAM activities described in the
Biennial Progress Report include:
• On behalf of NICEATM and
ICCVAM, NIEHS signed an amendment
to an international cooperation
agreement to add the Republic of Korea
and its Korean Center for the Validation
of Alternative Methods (KoCVAM) to
the International Cooperation on
VerDate Mar<15>2010
14:45 Jun 12, 2012
Jkt 226001
Alternative Test Methods (ICATM).
ICATM was established in 2009 by the
United States, the European Union,
Japan, and Canada to expedite the
worldwide validation and regulatory
acceptance of improved alternative test
methods.
• The Organisation for Economic Cooperation and Development (OECD)
adopted an international guidance
document prepared by NICEATM and
ICCVAM that describes how to use two
cytotoxicity assays to reduce animal use
for testing required to determine the
poisoning potential of chemicals.
NICEATM led the international
validation studies for the two
cytotoxicity assays, which can reduce
animal use by up to 50% for each test.
• Federal agencies and the OECD
adopted several new versions and
applications of the murine local lymph
node assay (LLNA); an alternative
method recommended by ICCVAM to
assess whether substances may cause
allergic contact dermatitis. The test
methods reduce animal use for each test
by 20–40% and support expanded use
of the LLNA for nearly all testing
situations. Two new ‘‘green’’ versions of
the LLNA were adopted that do not
require radioactive reagents and will
allow expanded use of the LLNA in
laboratories worldwide.
• Federal agencies adopted ICCVAM
recommended alternative test methods
and procedures that will further reduce,
refine, and replace animal use for eye
safety testing. These include the routine
use of medications to avoid most if not
all pain and distress when it is
necessary to use animals for required
safety testing, and the first in vitro test
method that can be used in a ‘‘bottomup’’ approach to identify substances that
are not considered eye hazards.
• NICEATM, ICCVAM, and their
ICATM partners convened the first
international workshop on alternative
methods for human and veterinary
vaccine potency and safety testing. The
workshop reviewed the state of the
science of alternative methods, and
recommended priority research needed
to develop improved and more efficient
test methods that can also reduce,
refine, and replace animal use. A
focused workshop on human and
veterinary rabies vaccine test methods
was held in 2011 and additional focused
workshops are planned for 2012 and
2013.
• ICCVAM completed international
evaluation of an in vitro test method
proposed as a screening test to identify
substances with potential endocrine
activity. The test method uses
engineered human cells to identify
substances that induce or inhibit
PO 00000
Frm 00044
Fmt 4703
Sfmt 9990
activation of the human estrogen
receptor. Use of this test method may
reduce the number of animals necessary
for endocrine disruptor screening.
• NICEATM and ICCVAM convened
two Best Practices for Regulatory Safety
Testing Workshops to promote the use
of improved and more efficient test
methods that can also reduce, refine,
and replace animal use. Participants
learned how to select and use approved
alternative methods to assess the safety
or potential hazards of chemicals and
products.
Background Information on ICCVAM
and NICEATM
ICCVAM is an interagency committee
composed of representatives from 15
Federal regulatory and research agencies
that require, use, generate, or
disseminate toxicological and safety
testing information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
with regulatory applicability and
promotes the scientific validation and
regulatory acceptance of toxicological
and safety testing methods that more
accurately assess the safety and hazards
of chemicals and products and that
reduce, refine (enhance animal wellbeing and lessen or eliminate pain and
distress), or replace animal use. The
ICCVAM Authorization Act of 2000 (42
U.S.C. 285l–3) established ICCVAM as a
permanent interagency committee of the
NIEHS under NICEATM. NICEATM
administers ICCVAM, provides
scientific and operational support for
ICCVAM-related activities, and
conducts independent validation
studies to assess the usefulness and
limitations of new, revised, and
alternative test methods and strategies.
NICEATM and ICCVAM welcome the
public nomination and submission of
new, revised, and alternative test
methods and strategies applicable to the
needs of U.S. Federal agencies.
Additional information about NICEATM
and ICCVAM can be found on the
NICEATM–ICCVAM Web site (https://
iccvam.niehs.nih.gov).
Dated: June 4, 2012.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2012–14436 Filed 6–12–12; 8:45 am]
BILLING CODE 4150–01–P
E:\FR\FM\13JNN1.SGM
13JNN1
Agencies
[Federal Register Volume 77, Number 114 (Wednesday, June 13, 2012)]
[Notices]
[Pages 35393-35394]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-14436]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Biennial Progress Report of the Interagency Coordinating
Committee on the Validation of Alternative Methods (ICCVAM)
AGENCY: Division of the National Toxicology Program (DNTP), National
Institute of Environmental Health Sciences (NIEHS), National Institutes
of Health (NIH).
ACTION: Availability of Report.
-----------------------------------------------------------------------
SUMMARY: The NTP Interagency Center for the Evaluation of Alternative
Toxicological Methods (NICEATM) announces the availability of the
Biennial Progress Report 2010-2011: Interagency Coordinating Committee
on the Validation of Alternative Methods. The report was prepared in
accordance with requirements of the ICCVAM Authorization Act of 2000
(42 U.S.C. 285l-3).
The Biennial Progress Report describes activities and progress by
NICEATM and ICCVAM during the period from January 2010 through December
2011. During the past two years, NICEATM, ICCVAM, and ICCVAM member
agencies contributed to the national and international endorsement and
adoption of 14 new and updated alternative safety testing methods.
Since ICCVAM was established, NICEATM, ICCVAM, and the ICCVAM member
agencies have contributed to the regulatory acceptance of over 50
alternative methods that can be used to protect the health of people,
animals, and the environment while reducing, refining, and replacing
animal use.
The Biennial Progress Report is available on the NICEATM-ICCVAM Web
site at https://iccvam.niehs.nih.gov/about/ICCVAMrpts.htm. Copies can
also be requested from NICEATM (see ``ADDRESSES'').
ADDRESSES: Requests for copies of the report should be sent by mail,
fax, or email to Dr. William S. Stokes, Director, NICEATM, NIEHS, P.O.
Box 12233, Mail Stop: K2-16, Research Triangle Park, NC 27709,
(telephone) 919-541-2384, (fax) 919-541-0947, (email)
niceatm@niehs.nih.gov. Courier address: NICEATM, NIEHS, Room 2034, 530
Davis Drive, Morrisville, NC 27560.
[[Page 35394]]
FOR FURTHER INFORMATION CONTACT: Dr. William S. Stokes, NICEATM
Director (phone 919-541-2384 or niceatm@niehs.nih.gov).
SUPPLEMENTARY INFORMATION:
Background
The ICCVAM Authorization Act of 2000 established ICCVAM as a
permanent interagency committee of NIEHS under NICEATM. The Act directs
ICCVAM to coordinate interagency technical reviews of proposed new,
revised, and alternative testing methods, including those that may
reduce, refine (enhance animal well-being and lessen or avoid pain and
distress), and replace animal use. ICCVAM prepares test method
recommendations based on their scientific validity for regulatory
safety testing, and submits these recommendations through the HHS
Secretary (or designee) to U.S. Federal Agencies for adoption
decisions.
A provision of the ICCVAM Authorization Act states that ICCVAM
shall prepare ``reports to be made available to the public on its
progress under this Act,'' with the first report to be completed within
12 months of enactment of the Act, and subsequent reports to be made
biennially thereafter. The fifth ICCVAM biennial progress report, which
summarizes ICCVAM activities and accomplishments for the years 2010 and
2011, is now available.
Summary of Report Highlights
The Biennial Progress Report describes new initiatives and progress
by NICEATM and ICCVAM during the period from January 2010 through
December 2011. During the past two years, NICEATM, ICCVAM, and ICCVAM
member agencies contributed to the national and international
endorsement and adoption of 14 new and updated alternative safety
testing methods. Since ICCVAM was established, NICEATM, ICCVAM, and the
ICCVAM member agencies have contributed to the regulatory acceptance of
over 50 alternative methods that can be used to protect and improve the
health of people, animals, and the environment while reducing,
refining, and replacing animal use.
Selected highlights of NICEATM and ICCVAM activities described in
the Biennial Progress Report include:
On behalf of NICEATM and ICCVAM, NIEHS signed an amendment
to an international cooperation agreement to add the Republic of Korea
and its Korean Center for the Validation of Alternative Methods
(KoCVAM) to the International Cooperation on Alternative Test Methods
(ICATM). ICATM was established in 2009 by the United States, the
European Union, Japan, and Canada to expedite the worldwide validation
and regulatory acceptance of improved alternative test methods.
The Organisation for Economic Co-operation and Development
(OECD) adopted an international guidance document prepared by NICEATM
and ICCVAM that describes how to use two cytotoxicity assays to reduce
animal use for testing required to determine the poisoning potential of
chemicals. NICEATM led the international validation studies for the two
cytotoxicity assays, which can reduce animal use by up to 50% for each
test.
Federal agencies and the OECD adopted several new versions
and applications of the murine local lymph node assay (LLNA); an
alternative method recommended by ICCVAM to assess whether substances
may cause allergic contact dermatitis. The test methods reduce animal
use for each test by 20-40% and support expanded use of the LLNA for
nearly all testing situations. Two new ``green'' versions of the LLNA
were adopted that do not require radioactive reagents and will allow
expanded use of the LLNA in laboratories worldwide.
Federal agencies adopted ICCVAM recommended alternative
test methods and procedures that will further reduce, refine, and
replace animal use for eye safety testing. These include the routine
use of medications to avoid most if not all pain and distress when it
is necessary to use animals for required safety testing, and the first
in vitro test method that can be used in a ``bottom-up'' approach to
identify substances that are not considered eye hazards.
NICEATM, ICCVAM, and their ICATM partners convened the
first international workshop on alternative methods for human and
veterinary vaccine potency and safety testing. The workshop reviewed
the state of the science of alternative methods, and recommended
priority research needed to develop improved and more efficient test
methods that can also reduce, refine, and replace animal use. A focused
workshop on human and veterinary rabies vaccine test methods was held
in 2011 and additional focused workshops are planned for 2012 and 2013.
ICCVAM completed international evaluation of an in vitro
test method proposed as a screening test to identify substances with
potential endocrine activity. The test method uses engineered human
cells to identify substances that induce or inhibit activation of the
human estrogen receptor. Use of this test method may reduce the number
of animals necessary for endocrine disruptor screening.
NICEATM and ICCVAM convened two Best Practices for
Regulatory Safety Testing Workshops to promote the use of improved and
more efficient test methods that can also reduce, refine, and replace
animal use. Participants learned how to select and use approved
alternative methods to assess the safety or potential hazards of
chemicals and products.
Background Information on ICCVAM and NICEATM
ICCVAM is an interagency committee composed of representatives from
15 Federal regulatory and research agencies that require, use,
generate, or disseminate toxicological and safety testing information.
ICCVAM conducts technical evaluations of new, revised, and alternative
safety testing methods with regulatory applicability and promotes the
scientific validation and regulatory acceptance of toxicological and
safety testing methods that more accurately assess the safety and
hazards of chemicals and products and that reduce, refine (enhance
animal well-being and lessen or eliminate pain and distress), or
replace animal use. The ICCVAM Authorization Act of 2000 (42 U.S.C.
285l-3) established ICCVAM as a permanent interagency committee of the
NIEHS under NICEATM. NICEATM administers ICCVAM, provides scientific
and operational support for ICCVAM-related activities, and conducts
independent validation studies to assess the usefulness and limitations
of new, revised, and alternative test methods and strategies. NICEATM
and ICCVAM welcome the public nomination and submission of new,
revised, and alternative test methods and strategies applicable to the
needs of U.S. Federal agencies. Additional information about NICEATM
and ICCVAM can be found on the NICEATM-ICCVAM Web site (https://iccvam.niehs.nih.gov).
Dated: June 4, 2012.
John R. Bucher,
Associate Director, National Toxicology Program.
[FR Doc. 2012-14436 Filed 6-12-12; 8:45 am]
BILLING CODE 4150-01-P